CGNX: Stock thesis & analysis
As of 10-01-2026
📁 From our research archive: this thesis was generated on 10-01-2026 and may not reflect our current view. See the latest research →
Cognex is a high-quality machine-vision franchise with a 29% operating margin and leadership in a Technology sector currently ranked #1 in the macro regime, but valuation discipline fails here: P/E of 58x and P/FCF of 52x against an ROE of just 11% leaves little margin of safety, scoring 14/100 on valuation. Coverage is thin, under-followed with just 1 tracked holder and persistence of only two quarters, which looks structural given the stock's mid-cap size rather than a fundamental red flag, so it is not a reason to discount the thesis on its own. The stretched multiple combined with a recent track record of stop-outs on marginal-conviction entries argues for waiting rather than chasing at the current price.
Catalysts to watch
- Potential industrial capex re-acceleration tied to manufacturing expansion data
- Next quarterly earnings report, follow-through on the September 22 8-K disclosure
- Possible analyst upgrades following the two recent neutral initiations if margins beat expectations
Key risks
- Valuation is elevated at 58x earnings and 52x free cash flow versus an 11% ROE
- Thin institutional coverage with only one tracked holder limits confirming demand
- High leverage with debt to equity of 4.45 adds balance sheet risk in a downturn
- Machine-vision end markets are cyclical and tied to industrial capex spending
What would change the view
- Stock breaks below $52.00
- Operating margin falls below 24% for two consecutive quarters
- P/FCF expands further while FCF growth decelerates below 5% YoY, confirming valuation is outrunning fundamentals